- Home
- VERV vs MGTX Comparison
VERV vs MGTX Comparison
Compare VERV & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- MGTX
- Stock Information
- Founded
- VERV 2018
- MGTX 2015
- Country
- VERV United States
- MGTX United States
- Employees
- VERV N/A
- MGTX N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERV Health Care
- MGTX Health Care
- Exchange
- VERV Nasdaq
- MGTX Nasdaq
- Market Cap
- VERV 475.0M
- MGTX 479.9M
- IPO Year
- VERV 2021
- MGTX N/A
- Fundamental
- Price
- VERV $6.14
- MGTX $6.26
- Analyst Decision
- VERV Strong Buy
- MGTX Strong Buy
- Analyst Count
- VERV 4
- MGTX 2
- Target Price
- VERV $25.75
- MGTX $23.50
- AVG Volume (30 Days)
- VERV 1.5M
- MGTX 337.9K
- Earning Date
- VERV 02-25-2025
- MGTX 03-13-2025
- Dividend Yield
- VERV N/A
- MGTX N/A
- EPS Growth
- VERV N/A
- MGTX N/A
- EPS
- VERV N/A
- MGTX N/A
- Revenue
- VERV $24,396,000.00
- MGTX $13,929,000.00
- Revenue This Year
- VERV $97.47
- MGTX N/A
- Revenue Next Year
- VERV N/A
- MGTX $1,391.84
- P/E Ratio
- VERV N/A
- MGTX N/A
- Revenue Growth
- VERV 219.91
- MGTX 108.24
- 52 Week Low
- VERV $4.31
- MGTX $3.85
- 52 Week High
- VERV $19.34
- MGTX $7.37
- Technical
- Relative Strength Index (RSI)
- VERV 53.75
- MGTX 53.41
- Support Level
- VERV $5.32
- MGTX $5.66
- Resistance Level
- VERV $6.87
- MGTX $6.12
- Average True Range (ATR)
- VERV 0.52
- MGTX 0.39
- MACD
- VERV -0.00
- MGTX -0.02
- Stochastic Oscillator
- VERV 56.74
- MGTX 62.26
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.